A
DNTH icon

AlphaQuest’s Dianthus Therapeutics DNTH Stock Holding History

AlphaQuest’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,856
Closed -$76.5K – 584
2025
Q4 		$76.5K Buy
1,856
+525
+39% +$20.4K ﹤0.01% 1833
2025
Q3 		$52.4K Sell
1,331
-3,697
-74% -$94.5K ﹤0.01% 1919
2025
Q2 		$93.7K Buy
+5,028
New +$94.3K 0.01% 1449
2025
Q1 		– Sell
-4,197
Closed -$91.5K – 2038
2024
Q4 		$91.5K Buy
4,197
+3,072
+273% +$79K 0.01% 1123
2024
Q3 		$30.8K Buy
1,125
+1,124
+112,400% +$31.3K ﹤0.01% 1477
2024
Q2 		$26 Buy
+1
New +$24 ﹤0.01% 1514

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AlphaQuest's DNTH Position: Q1 2026 in Review

AlphaQuest sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 1,856 shares — an estimated $76.5K sold.

AlphaQuest first reported a position in DNTH in Q2 2024 and held it in 6 quarters. The position peaked at $93.7K in Q2 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • AlphaQuest reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 1,856 Dianthus Therapeutics shares in Q1 2026, an estimated $76.5K.
  • AlphaQuest first reported a position in Dianthus Therapeutics in Q2 2024 and held it in 6 quarters.
  • AlphaQuest's Dianthus Therapeutics position peaked at $93.7K in Q2 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.